Study Summary
This trial studies how well a drug helps treat Multiple System Atrophy with a form of dizziness. It has 4 steps and lasts 20 weeks.
- Neurogenic Orthostatic Hypotension
- Multiple System Atrophy
Treatment Effectiveness
Phase-Based Effectiveness
Study Objectives
1 Primary · 2 Secondary · Reporting Duration: 8-week randomized withdrawal period (Week 12 to Week 20)
Trial Safety
Phase-Based Safety
Awards & Highlights
Trial Design
5 Treatment Groups
Long-Term Extension Period
1 of 5
Ampreloxetine (Open Label)
1 of 5
Ampreloxetine
1 of 5
Ampreloxetine (Randomized Withdrawal)
1 of 5
Placebo
1 of 5
Active Control
Non-Treatment Group
102 Total Participants · 5 Treatment Groups
Primary Treatment: Long-Term Extension Period · Has Placebo Group · Phase 3
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18+ · All Participants · 0 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Frequently Asked Questions
Has the US Food & Drug Administration sanctioned a Long-Term Extension Period?
"The safety of the Long-Term Extension Period has been judged as a 3, owing to its Phase 3 trial status and existing efficacy data. Additionally, there are numerous studies that attest to its security." - Anonymous Online Contributor
Is this medical experiment actively looking for participants?
"As seen on clinicaltrials.gov, recruitment for this medical trial is ongoing; the first post was made on March 1st 2023 and most recently updated on March 30th of the same year." - Anonymous Online Contributor
How many volunteers are being recruited for this trial?
"Affirmative. According to information available on clinicaltrials.gov, this medical experiment was first published on March 1st 2023 and is actively enrolling participants at the moment. The study requires 102 individuals from a single trial location." - Anonymous Online Contributor